Overview

• In the US INFORM survey of 550 adults on semaglutide, constant thoughts about food fell from 62% before treatment to 16% on treatment.
• Participants also reported declines in uncontrollable thoughts about food (53% to 15%) and in spending too much time thinking about food (63% to 15%).
• Sixty-four percent reported improved mental health, 76% reported developing a healthier lifestyle, 80% reported healthier habits, and 83% were satisfied with treatment.
• The real-world study relied on self-reported recall, included a majority female sample (86%), most had been on therapy at least four months, and used a validated Food Noise Questionnaire.
• The survey was conducted by Novo Nordisk with Market Track LLC and presented at the European Association for the Study of Diabetes 2025, with authors noting that causality remains unclear despite mechanistic plausibility for GLP-1 drugs.